At a Glance
- Company: UCB (Belgian biopharma)
- Location: Slough, UK
- Deal value: £500m joint capital investment
- Focus area: Immunology R&D and manufacturing
- Next steps: Advance medicines at Slough research hub
What happened?
UCB announced a major joint capital investment with the UK government through the Life Sciences Innovative Manufacturing Fund (LSIMF). The partnership, valued at £500 million, will boost UCB’s research and development efforts in immunological diseases at its Slough hub.
Why does it matter?
The investment strengthens UK life sciences manufacturing and R&D amid global competition, supporting job creation and innovation in immunology—a key area for UCB with products like Cimzia. It aligns with UK efforts to attract pharma investment post‑Brexit.
Who’s behind it?
UCB, a Belgian biopharma focused on neurology and immunology, partners with HM Treasury via LSIMF to enhance UK operations.
How was it achieved?
Funding from LSIMF enables expansion of UCB’s Slough site, currently under development, for advanced medicines in immunology.
What’s next?
UCB will advance pipeline candidates at the upgraded hub, with milestones tied to manufacturing innovation and clinical progress.
What are people saying?
UCB highlighted the boost as key to “innovation and execution” in UK life sciences.